WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.
| FactSnippet No. 1,665,535 |
13 Facts About WuXi AppTec
1.
2.
WuXi AppTec established services in synthetic chemistry in 2001, manufacturing process development in 2003, research manufacturing in 2004, bioanalytical services in 2005, service biology in 2006, and toxicology and formulation in 2007.
| FactSnippet No. 1,665,536 |
4.
In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc, a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St Paul, MN; Philadelphia, PA; and Atlanta, GA.
| FactSnippet No. 1,665,538 |
5.
WuXi AppTec opened a large-scale manufacturing facility in Jinshan in 2010.
| FactSnippet No. 1,665,539 |
8.
That year WuXi AppTec entered into a joint venture with MedImmune, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6 antibody for rheumatoid arthritis for the Chinese market.
| FactSnippet No. 1,665,542 |
9.
In 2013, WuXi AppTec formed a joint venture with the global clinical contract research organization PRA International to build a clinical research business in China.
| FactSnippet No. 1,665,543 |
10.
In 2014, WuXi AppTec opened a new biologics biosafety testing facility in Suzhou.
| FactSnippet No. 1,665,544 |
11.
In 2017, WuXi AppTec acquired HD Biosciences, a biology focused preclinical drug discovery contract research organization.
| FactSnippet No. 1,665,545 |
12.
WuXi AppTec provides services to its customers primarily in the pharmaceutical, biotech, and other life science industries, as well as research institutes, disease-focused and non-profit foundations.
| FactSnippet No. 1,665,546 |
13.
In 2015, the company launched the subsidiary WuXi AppTec NextCODE following the acquisition of NextCODE Health, a bioinformatics startup company which emerged from the Icelandic firm deCODE genetics in 2013.
| FactSnippet No. 1,665,547 |